Drug
Mavrilimumab
Mavrilimumab: highest development phase Phase 2/3, developed by Kiniksa Pharmaceuticals. 5 trial records tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Kiniksa Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| mavrilimumab NCT04447469 | Phase 2/3 | COVID |
| Mavrilimumab NCT04399980 | Phase 2 | COVID 19 |
| Mavrilimumab NCT04492514 | Phase 2 | COVID 19 |
| mavrilimumab NCT03827018 | Phase 2 | Giant Cell Arteritis |
| Mavrilimumab NCT04463004 | Phase 2 | COVID-19 |
Latest
No recent events.
Follow Mavrilimumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.